The role of cytotoxic chemotherapy in the management of progressive glioblastoma
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
What is the impact of cytotoxic chemotherapy on disease control and survival in the adult patient with progressive glioblastoma?
This recommendation applies to adults patients with progressive glioblastoma.
Temozolomide is recommended as superior to procarbazine in patients with first relapse of glioblastoma after having received nitrosourea chemotherapy or no prior cytotoxic chemotherapy at the time of initial therapy.
The use of BCNU-impregnated biodegradable polymer wafers is recommended in the management of progressive glioblastoma as a surgical adjunct when cytoreductive surgery is indicated, taking into account the associated toxicities seen with this modality.
Consideration of a variety of cytotoxic chemotherapy agents of uncertain benefit is recommended in the setting of progressive glioblastoma based on the judgment of the treating physician taking into account the individual patients prior treatment exposure, systemic health, and likelihood of tolerance of the toxicities of any given agent. It is recommended in such cases that enrollment in available clinical trials be encouraged.
- The role of cytotoxic chemotherapy in the management of progressive glioblastoma
Journal of Neuro-Oncology
Volume 118, Issue 3 , pp 501-555
- Cover Date
- Print ISSN
- Online ISSN
- Springer US
- Additional Links
- Industry Sectors
- Author Affiliations
- 1. Department of Neurosurgery, Emory University School of Medicine, Atlanta, GA, USA
- 2. Dana-Farber Cancer Institute, Department of Neurology, Brigham and Women’s Cancer Center, Boston, MA, USA
- 3. Department of Neurosurgery, Henry Ford Health System, Detroit, MI, USA